Loading clinical trials...
Loading clinical trials...
The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the dysregulation of the control of COVID-19 infection.
Single-center, prospective, open-ended, interventional study with minimal risks and constraints. Patients will be divided into 3 groups: patients not infected with COVID-19, patients infected with COVID-19 not hospitalized, patients infected with COVID-19 hospitalized.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Foch hospital
Suresnes, France
Start Date
October 19, 2020
Primary Completion Date
July 19, 2022
Completion Date
July 19, 2022
Last Updated
August 3, 2022
91
ACTUAL participants
Baseline and during hospitalization blood samples
OTHER
Baseline blood sample
OTHER
Lead Sponsor
Hopital Foch
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06355232